MKI67 and growth hormone-producing pituitary gland neoplasm: New immune biomarkers may be integrated into those that are actually available, such as the Ki-67, the somatostatin receptor and the cytokeratin pattern, for a personalized therapy, based on the patient’s profile [35, 120] and may promote the use of personalized and target therapy in aggressive and multi-drug resistant somatotropinomas, such as VEGF and m-TOR inhibitors and immune-therapy with monoclonal antibodies against immune-check points.